Sterling Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Sterling Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.54K	Sell	100 -679	-87%	-$13.5K	﹤0.01%	2923
2026 Q1	$15.2K	Sell	779 -308	-28%	-$6.91K	﹤0.01%	2146
2025 Q4	$39.5K	Sell	1,087 -34	-3%	-$1.12K	﹤0.01%	1893
2025 Q3	$24.9K	Buy	1,121 +682	+155%	+$11.1K	﹤0.01%	2036
2025 Q2	$4.25K	Buy	439 +308	+235%	+$3K	﹤0.01%	2596
2025 Q1	$1.03K	Sell	131 -95	-42%	-$743	﹤0.01%	2804
2024 Q4	$1.85K	Buy	+226	New	+$3.52K	﹤0.01%	2802

Other funds holding ZBIO

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Sterling Capital Management's ZBIO Position: Q2 2026 in Review

Sterling Capital Management reduced its Zenas BioPharma (ZBIO) stake by 87% in Q2 2026, selling an estimated $13.5K and leaving 100 shares worth $2.54K. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Sterling Capital Management first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $39.5K in Q4 2025. 17 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Sterling Capital Management held 100 shares of Zenas BioPharma worth $2.54K as of Q2 2026.
Sterling Capital Management sold 679 Zenas BioPharma shares in Q2 2026, an estimated $13.5K.
Zenas BioPharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2923 holding.
Sterling Capital Management first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
Sterling Capital Management's Zenas BioPharma position peaked at $39.5K in Q4 2025.
17 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.